Cargando…

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience

Since 2020, COVID-19 pandemic has spread worldwide causing a huge number of cases and casualties. Among direct anti SARS-CoV-2 agents available for the treatment of COVID-19, only remdesivir and casirivimab/imdevimab have been approved for severe disease. As they act at different levels in blocking...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moriello, Nicola Schiano, Buonomo, Antonio Riccardo, Scotto, Riccardo, Pinchera, Biagio, Sarno, Marina, Fusco, Ludovica, Viceconte, Giulio, Iuliano, Antonio, Zappulo, Emanuela, Foggia, Maria, Villari, Riccardo, Gentile, Ivan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859639/ https://www.ncbi.nlm.nih.gov/pubmed/36713627 http://dx.doi.org/10.1016/j.heliyon.2023.e13126

Ejemplares similares

Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience
por: Gentile, Ivan, et al.
Publicado: (2021)

Update on the Management of Surgical Site Infections
por: Pinchera, Biagio, et al.
Publicado: (2022)

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
por: Scotto, Riccardo, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy)
por: Gentile, Ivan, et al.
Publicado: (2022)

A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19
por: Scotto, Riccardo, et al.
Publicado: (2022)

Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge
por: Scotto, Riccardo, et al.
Publicado: (2022)

Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19
por: Pinchera, Biagio, et al.
Publicado: (2023)

Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study
por: Viceconte, Giulio, et al.
Publicado: (2023)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Diabetes and COVID-19: The potential role of mTOR
por: Pinchera, B., et al.
Publicado: (2022)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients
por: Biagio, Pinchera, et al.
Publicado: (2022)

Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma
por: Capoluongo, Ettore, et al.
Publicado: (2021)

Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia
por: Scotto, Riccardo, et al.
Publicado: (2021)

Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?
por: Nardelli, Carmela, et al.
Publicado: (2021)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience
por: Pinchera, Biagio, et al.
Publicado: (2022)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
por: Dioverti, M Veronica, et al.
Publicado: (2022)

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2021)

Retraction to “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
por: Hegazy, Sahar K., et al.
Publicado: (2023)

mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study
por: Pinchera, Biagio, et al.
Publicado: (2022)

Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves
por: Cattaneo, Letizia, et al.
Publicado: (2023)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2019)

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
por: Moccia, Marcello, et al.
Publicado: (2022)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cid04rq9krqvvidhpf0hcutvkv